Kanaph Therapeutics Inc. (0082N0.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
Kanaph Therapeutics Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 4.25 bn KRW | 5.56 bn KRW |
| Gross profit | 4.25 bn KRW | 5.56 bn KRW |
| Operating income | -4.72 bn KRW | -4.27 bn KRW |
| EBIT | -23.34 bn KRW | -31.71 bn KRW |
| Net income | -28.27 bn KRW | -35.56 bn KRW |
| Diluted EPS – continuing operations | -2,182.08 KRW | -2,744.63 KRW |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Kanaph Therapeutics Inc.
Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker therapy for patients with wet age-related macular degeneration and geographic atrophy, which has completed preclinical stage; KNP-502, a dual antagonist of the prostaglandin E2 receptors EP2 and EP4 that is in Phase 1 clinical trials to overcome PGE2-mediated immunosuppression within the tumor microenvironment; KNP-503, a SHP2 allosteric inhibitor, which is in preclinical trials for the treatment of various KRAS-mutated cancers, including non-small cell lung cancer, colorectal cancer, and glioblastoma; and KNP-504, a SOS1 inhibitor, which has completed preclinical trials for the treatment of RAS-mutated cancers, including non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and NF1-mutant solid tumor. It also discovers KNP-701, an anti-cMET and anti-EGFR bispecific ADC for treating non-small cell lung cancer. Kanaph Therapeutics Inc. was founded in 2019 and is headquartered in Seoul, South Korea.
More stocks
- AUBURN NATIONAL BANCORPORATION, INC (AUBN)
- Groupe Minoteries SA (GMI.SW)
- Bflysoft Co. Ltd. (148780.KQ)
- Microvast Holdings, Inc. (MVST)
- Bien Sparebank ASA (BIEN.OL)
- Favelle Favco Bhd (7229.KL)
- Sunfon Construction Co Ltd (5514.TWO)
- Crossject (ALCJ.PA)
- NEOOTO Co. Ltd (212560.KQ)
- Vaxart, Inc. (VXRT)
- Nonthavej Hospital Public Company Limited (NTV.BK)
- iHeartMedia, Inc. (IHRT)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.